Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Perrone

Showing results (221-230 of 272) with videos related to

Pageof 28
Sort By:
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 23, 2020
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare systemSilvia Riva, Fabio Efficace, Massimo Di Maio, et al.
Translational Lung Cancer Research|May 20, 2021
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancerVictoria Foy, Colin R Lindsay, Alexandra Carmel, et al.
The Lancet. Oncology|April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trialSandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Frontiers in Medicine|December 26, 2022
A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trialValentina D'Angelo, Maria Carmela Piccirillo, Massimo Di Maio, et al.
Lung Cancer (Amsterdam, Netherlands)|February 3, 2012
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trialsMassimo Di Maio, Simona Signoriello, Alessandro Morabito, et al.
Pageof 28

Showing results (221-230 of 272) with videos related to

Sort By:
Pageof 28
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 23, 2020
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare systemSilvia Riva, Fabio Efficace, Massimo Di Maio, et al.
Translational Lung Cancer Research|May 20, 2021
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancerVictoria Foy, Colin R Lindsay, Alexandra Carmel, et al.
The Lancet. Oncology|April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trialSandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Frontiers in Medicine|December 26, 2022
A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trialValentina D'Angelo, Maria Carmela Piccirillo, Massimo Di Maio, et al.
Lung Cancer (Amsterdam, Netherlands)|February 3, 2012
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trialsMassimo Di Maio, Simona Signoriello, Alessandro Morabito, et al.
Pageof 28